Nav: Home

Researchers identify new process to raise natural armies of cancer-targeting T lymphocytes

February 14, 2017

PHOENIX - Mayo Clinic and University of Washington researchers have discovered a new culture method that unlocks the natural fighter function of immune T cells when they are passing through the bloodstream. This allows T cell armies to be raised directly from blood that naturally recognize and target proteins that are present on most human cancers. The results are published in the Feb. 14 issue of Oncotarget.

"Even though it is relatively easy to collect billions of T cells directly from patient blood, it has historically proved difficult or impossible to unleash those T cells' natural ability to recognize and target cancer cells," says Peter Cohen, M.D., a Mayo Clinic immunotherapist who co-led the study with Mayo Clinic immunologist Sandra Gendler, Ph.D., and University of Washington immunotherapist Nora Disis, M.D.

"Our method strictly employs natural signals to activate the immune blood cells outside the body," says Dr. Disis. "This gives rise to expanded armies of T cells, which specifically recognize proteins that are present on cancer cells and which can be reinfused into patients for therapeutic evaluations in future clinical trials."

The research team tested the method's ability to stimulate T cell responses against MUC1, a protein expressed by a large majority of patients' cancers, including breast, pancreatic, lung, colorectal, ovarian, kidney, bladder, and multiple myeloma. Also tested were HER2/neu, a protein present in one-quarter to half of many types of cancer, and CMVpp65, a protein present in half of primary brain tumors.

"Our culture method is similar to performing a vaccination procedure entirely outside the body, and it was successful for all three proteins," adds Dr. Gendler.

The researchers found that T cells traveling within the bloodstream naturally remained locked in a resting state unless they were exposed to natural alarm signals normally triggered only by serious infections. Once outside the body, however, the T cells could be exposed safely to such alarm signals to unleash their fighter function. When the T cell cultures also were exposed to MUC1, HER2/neu, CMVpp65 or other cancer-associated proteins, it only required three weeks to grow out natural T cell armies trained to recognize and target cancers expressing these proteins.

"The cancer-associated proteins we have tested so far already target the majority of human cancers, and it is likely that this culture method will extend to many additional proteins present on cancer cells," explains Dr. Gendler. Dr. Cohen adds, "We are pleased to help other investigators implement our culture method for their own cancer-associated proteins of interest."
-end-
Other key contributors to the study are:

Latha Pathangey, Mayo Clinic
Dustin McCurry, Mayo Clinic
Ana Dominguez, Mayo Clinic
Girish Pathangey, Mayo Clinic
Jessica Gorman, Mayo Clinic
Laurie Mihalik, Mayo Clinic
Yushe Dang, Ph.D., University of Washington

About Mayo Clinic

Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.

Mayo Clinic

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".